A new market study, titled “Epiomic Epidemiology Series: Chronic Heart Failure Forecast in 12 Major Markets 2018-2028”, has been featured on WiseGuyReports.
Chronic heart failure (CHF) is a chronic disease during which the heart is not able to supply sufficient blood flow to the body. Exacerbations of CHF are characterised by dyspnoea at rest or on exertion and worsening fluid retention, apparent as lung congestion and/or swollen ankles and legs. The disease is associated with toxic, inflammatory and infective heart damage, structural, metabolic and genetic heart abnormalities, as well as cardiovascular risk factors, such as smoking, sedentary lifestyle, unhealthy diet and alcohol consumption.
This report provides the current prevalent population for chronic heart failure across 12 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Russia, Japan, China, Brazil & India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, patient populations with the two types of chronic heart failure, as well as several of the main symptoms and co-morbidities of chronic heart failure have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for chronic heart failure include:
- Arterial hypertension
- Coronary artery disease
- Atrial fibrillation
- Diabetes mellitus
- Metabolic syndrome
- Renal dysfunction
- Chronic obstructive pulmonary disease (COPD)
- Pulmonary hypertension
- Sleep apnoea
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Able to quantify patient populations in global chronic heart failure market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the prevalence of the subdivided types of chronic heart failure and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Provide a level of understanding on the impact from specific co-morbid conditions on chronic heart failure’s prevalent population.
- Identify sub-populations within chronic heart failure which require treatment.
- Gain an understanding of the specific markets that have the largest number of chronic heart failure patients.
Table of Contents
- LIST OF TABLES AND FIGURES
- CAUSE OF THE DISEASE
- RISK FACTORS & PREVENTION
- DIAGNOSIS OF THE DISEASE
- VARIATION BY GEOGRAPHY/ETHNICITY
- DISEASE PROGNOSIS & CLINICAL COURSE
- KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
- METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
- TOP-LINE PREVALENCE FOR CHRONIC HEART FAILURE
- CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION
- FEATURES OF CHF-REF PATIENTS
- COMORBID CONDITIONS OF CHF-REF PATIENTS
- CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION
- FEATURES OF CHF-PEF PATIENTS
- COMORBID CONDITIONS OF CHF-PEF PATIENTS
- ABBREVIATIONS USED IN THE REPORT
- OTHER BLACK SWAN ANALYSIS PUBLICATIONS
- BLACK SWAN ANALYSIS ONLINE PATIENT-BASED DATABASES
- PATIENT-BASED OFFERING
- ONLINE PRICING DATA & PLATFORMS
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)